EA201492026A1 - Способ изготовления фармацевтической лекарственной формы, содержащей нифедипин и кандесартан цилексетил - Google Patents

Способ изготовления фармацевтической лекарственной формы, содержащей нифедипин и кандесартан цилексетил

Info

Publication number
EA201492026A1
EA201492026A1 EA201492026A EA201492026A EA201492026A1 EA 201492026 A1 EA201492026 A1 EA 201492026A1 EA 201492026 A EA201492026 A EA 201492026A EA 201492026 A EA201492026 A EA 201492026A EA 201492026 A1 EA201492026 A1 EA 201492026A1
Authority
EA
Eurasian Patent Office
Prior art keywords
candesartan
form containing
cylexethyl
nifedipin
manufacturing
Prior art date
Application number
EA201492026A
Other languages
English (en)
Inventor
Адриан Функэ
Гюнтер Майер
Мартина Смикалла
Андреас Менерс
Маркус Виргес
Даниела Брок
Сара Юст
Петер Кляйнебудде
Клаус Кноп
Йохен Аксель Цайтлер
Рольф-Антон Бёггеринг
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201492026A1 publication Critical patent/EA201492026A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к способам изготовления фармацевтической лекарственной формы, содержащей нифедипин и кандесартан цилексетил и, при необходимости, по меньшей мере один диуретик, отличающимся тем, что происходит контролируемое (модифицированное) высвобождение в организм нифедипина и быстрое (немедленное) высвобождение (НВ) кандесартан цилексетила и, при необходимости, быстрое (немедленное) высвобождение (НВ) диуретика, а также к фармацевтическим лекарственным формам, которые могут быть получены указанными способами.
EA201492026A 2012-05-07 2013-05-02 Способ изготовления фармацевтической лекарственной формы, содержащей нифедипин и кандесартан цилексетил EA201492026A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167035 2012-05-07
EP13151946 2013-01-18
PCT/EP2013/059110 WO2013167453A1 (en) 2012-05-07 2013-05-02 Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil

Publications (1)

Publication Number Publication Date
EA201492026A1 true EA201492026A1 (ru) 2015-09-30

Family

ID=48289160

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492026A EA201492026A1 (ru) 2012-05-07 2013-05-02 Способ изготовления фармацевтической лекарственной формы, содержащей нифедипин и кандесартан цилексетил

Country Status (27)

Country Link
US (1) US9539176B2 (ru)
EP (1) EP2846777B1 (ru)
JP (1) JP6231553B2 (ru)
KR (1) KR20150007297A (ru)
CN (1) CN104507459A (ru)
AR (1) AR090940A1 (ru)
AU (1) AU2013258273A1 (ru)
BR (1) BR112014027618A2 (ru)
CA (1) CA2872542A1 (ru)
CL (1) CL2014002988A1 (ru)
CO (1) CO7190241A2 (ru)
CR (1) CR20140511A (ru)
DO (1) DOP2014000251A (ru)
EA (1) EA201492026A1 (ru)
EC (1) ECSP14025965A (ru)
ES (1) ES2612532T3 (ru)
GT (1) GT201400245A (ru)
HK (1) HK1204292A1 (ru)
IL (1) IL235040A0 (ru)
IN (1) IN2014DN09045A (ru)
MX (1) MX2014013320A (ru)
PE (1) PE20142284A1 (ru)
PH (1) PH12014502469A1 (ru)
SG (1) SG11201406363VA (ru)
TW (1) TW201410266A (ru)
UY (1) UY34786A (ru)
WO (1) WO2013167453A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9244004B2 (en) * 2013-08-08 2016-01-26 Stichting Sron—Netherlands Institute For Space Research Method and system for inspection of composite assemblies using terahertz radiation
US10071482B2 (en) 2015-08-19 2018-09-11 Ford Global Technologies, Llc Robotic vehicle painting instrument including a terahertz radiation device
US10365229B2 (en) * 2015-12-31 2019-07-30 Kaiser Optical Systems, Inc. Real-time characterization of pharmaceutical tablet coatings using Raman spectroscopy
DE102016222667A1 (de) * 2016-11-17 2018-05-17 Robert Bosch Gmbh Verfahren zum Betrieb einer Anlage zum Herstellen von pharmazeutischen Produkten
US10323932B1 (en) 2017-12-28 2019-06-18 Ford Motor Company System for inspecting vehicle bodies
JP7263047B2 (ja) 2019-02-25 2023-04-24 沢井製薬株式会社 フィルムコーティング錠剤
CN110411978B (zh) * 2019-07-26 2020-05-22 中国农业大学 一种物料均匀性检测设备及检测方法
JP7312676B2 (ja) 2019-11-13 2023-07-21 ナブテスコ株式会社 ブレーキ異常判定装置、ブレーキ状態記憶装置、異常判定方法、異常判定プログラム、及びブレーキ制御装置
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4426019A (en) 1981-10-15 1984-01-17 The Coca-Cola Company Membrane seal and knife combination for a post-mix beverage dispensing system
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
DE59000232D1 (de) 1989-02-11 1992-09-10 Bayer Ag Arzneimittel mit kontrollierter wirkstoffabgabe.
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
JP3398379B2 (ja) 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンｉｉ受容体遮断組成物
US5656650A (en) 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
WO2000059479A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
WO2003035039A1 (en) 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
WO2003080057A1 (fr) 2002-03-27 2003-10-02 Bayer Aktiengesellschaft Comprime-noyau de taille reduite contenant de la nifedipine
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
AU2003249492A1 (en) 2003-07-24 2005-02-14 Eswaran Krishnan Iyer Oral compositions for treatment of diseases
WO2005079751A2 (en) 2004-01-23 2005-09-01 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
WO2005070398A2 (en) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP2210888B1 (en) 2005-05-10 2013-04-24 Teva Pharmaceutical Industries, Ltd. Stable micronized candesartan cilexetil and methods for preparing thereof
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
CN101500630B (zh) 2006-07-03 2012-05-30 诺沃-诺迪斯克有限公司 用于注射装置的联结器
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
US20100041644A1 (en) 2006-11-28 2010-02-18 Laboratorios Liconsa, S. A. Stabilized solid pharmaceutical composition of candesartan cilexetil
JP5351490B2 (ja) 2007-10-25 2013-11-27 バイエル薬品株式会社 ニフェジピン含有有核錠剤およびその製法
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US20130224296A1 (en) 2010-09-03 2013-08-29 Bristol-Myers Squibb Company Drug Formulations Using Water Soluble Antioxidants

Also Published As

Publication number Publication date
HK1204292A1 (en) 2015-11-13
SG11201406363VA (en) 2014-11-27
IN2014DN09045A (ru) 2015-05-22
GT201400245A (es) 2015-08-25
JP2015515999A (ja) 2015-06-04
UY34786A (es) 2013-11-29
US9539176B2 (en) 2017-01-10
US20130309302A1 (en) 2013-11-21
WO2013167453A1 (en) 2013-11-14
CL2014002988A1 (es) 2015-03-13
AU2013258273A1 (en) 2014-11-13
CN104507459A (zh) 2015-04-08
BR112014027618A2 (pt) 2017-06-27
CA2872542A1 (en) 2013-11-14
EP2846777B1 (en) 2016-10-26
ECSP14025965A (es) 2015-12-31
TW201410266A (zh) 2014-03-16
CO7190241A2 (es) 2015-02-19
PH12014502469A1 (en) 2014-12-22
DOP2014000251A (es) 2014-12-31
CR20140511A (es) 2014-12-02
EP2846777A1 (en) 2015-03-18
PE20142284A1 (es) 2014-12-17
KR20150007297A (ko) 2015-01-20
ES2612532T3 (es) 2017-05-17
AR090940A1 (es) 2014-12-17
JP6231553B2 (ja) 2017-11-15
MX2014013320A (es) 2015-08-10
IL235040A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
EA201492026A1 (ru) Способ изготовления фармацевтической лекарственной формы, содержащей нифедипин и кандесартан цилексетил
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
EA201690521A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201491339A1 (ru) Замещенные аннеллированные пиримидины и триазины и их применение
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201690246A1 (ru) Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
EA201591087A1 (ru) Новые производные бензимидазола в качестве антагонистов рецептора ep4
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
IN2014DN08867A (ru)
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EA201790032A1 (ru) Бициклически замещённые урацилы и их применение
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
BR112015010136A2 (pt) derivados de oxazolidin-2-ona-pirimidina
EA201491818A1 (ru) Способ получения оптически чистых и необязательно замещенных производных 2-(1-гидроксиалкил)хромен-4-она и их применение при получении лекарственных препаратов
EA201591618A1 (ru) Замещенные имидазопиридазины
EA201690183A1 (ru) Замещенные пиразолопиридинамины
EA201600288A1 (ru) Замещенные фенилаланиновые производные
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
EA201590474A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
EA201590594A1 (ru) Макролидные производные, их получение и их терапевтическое использование
EA201501177A1 (ru) Фармацевтические композиции
MX346497B (es) Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos.